Biphenyl

Biphenyl

SCHEMBL3096874

c1ccc(-c2ccccc2)cc1.c1ccc2nccnc2c1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
NOTUM Q6P988 1/20 0.52
CCNB2 O95067 2/20 0.48
CDK1 P06493 2/20 0.48
CCNB1 P14635 2/20 0.48
CDK5 Q00535 2/20 0.48
CDK5R1 Q15078 2/20 0.48
CCNB3 Q8WWL7 2/20 0.48
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TGFBR1 P36897 1/20 0.43
ADORA2A P29274 1/20 0.43
ATM Q13315 1/20 0.42
PIK3CA P42336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3190528 0.91 ALDH1A1 (0.55) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL27830916 0.91 ALDH1A1 (0.55) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL28165605 0.90 NOTUM (0.71) ALDH1A1NOTUMCCNB2CDK1CCNB1
Quinoxaline SCHEMBL27549902 0.88 ALDH1A1 (0.52) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL5315 0.87 ALDH1A1 (0.58) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL30320908 0.87 ALDH1A1 (0.58) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL6928518 0.87 ALDH1A1 (0.58) ALDH1A1CCNB2CDK1CCNB1CDK5
Quinoxaline SCHEMBL29355228 0.87 ALDH1A1 (0.58) ALDH1A1CCNB2CDK1CCNB1CDK5
Biphenyl SCHEMBL28549078 0.85 ALDH1A1 (0.52) ALDH1A1NOTUMNPC1RAB9ANFKB1
Biphenyl SCHEMBL29127776 0.85 ALDH1A1 (0.52) ALDH1A1NOTUMNPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118480146-A Preparation method of polyprenol-based light-controlled antibacterial synergist 中国林业科学研究院林产化学工业研究所 2024-08-13 CN claimed
CN-1352809-A Conductive polymers QINITIK CO LTD (GB) 2002-06-05 CN claimed
CN-118480146-A Preparation method of polyprenol-based light-controlled antibacterial synergist 中国林业科学研究院林产化学工业研究所 2024-08-13 CN disclosed
CN-115028624-B Quinoxaline skeleton NN oxazoline ligand and synthetic method and application thereof 上海师范大学 2023-10-27 CN disclosed
CN-113045506-A Triphenylamine quinoxaline malononitrile, synthetic method thereof and method for detecting CN < - > 阜阳师范大学 2021-06-29 CN disclosed
EP-2694067-B1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE TERNA ZENTARIS GMBH (DE) 2015-08-26 EP disclosed
CN-103080114-B Benzene azole dithiophene organic semiconductor material and preparation method and application thereof OCEANS KING LIGHTING SCIENCE 2015-05-06 CN disclosed
US-8937068-B2 Pyridopyrazine derivatives and their use ZENTARIS GMBH (DE) 2015-01-20 US disclosed
US-8912189-B2 Pyridopyrazine derivatives and their use AETERNA ZENTARIS GMBH (DE) 2014-12-16 US disclosed
CN-102386330-B Quinoxaline derivative, and organic semiconductor device, electric field light emitting device, and electronic device which have the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-10-22 CN disclosed
US-8791118-B2 Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors AETERNA ZENTARIS GMBH (DE) 2014-07-29 US disclosed
CN-101215299-A Quinoxalines ligand iridium complexes and synthetic method thereof UNIV LIAONING (CN) 2008-07-09 CN disclosed
US-20070123494-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE ZENTARIS GMBH (DE) 2007-05-31 US disclosed
CN-1795195-A Novel pyridopyrazines and their use as kinase modulators ZENTARIS GMBH (DE) 2006-06-28 CN disclosed
CN-1777592-A Quinoxaline derivative, and organic semiconductor element, electroluminescent element and electronic device using the same SEMICONDUCTOR ENERGY LAB (JP) 2006-05-24 CN disclosed
CN-1711275-A Palladium and platinum complexes COVION ORGANIC SEMICONDUCTORS (DE) 2005-12-21 CN disclosed
CN-1531541-A Rhodium and iridium complexes �����л��뵼�����޹�˾ 2004-09-22 CN disclosed
CN-1352809-A Conductive polymers QINITIK CO LTD (GB) 2002-06-05 CN disclosed
CN-1309680-A heat curable epoxy composition VANTICO AG (CH) 2001-08-22 CN disclosed
US-4005022-A PIGMENT-DYE-POLYMER IN AN ALIPHATIC SATURATED HYDROCARBON PITNEY-BOWES, INC. (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123494-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE PLPBP, PDXK, MAP4K2 ALDH1A1 1192/4885NOTUM 3876/4885CCNB2 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.